Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Sympathomimetic with alpha adrenergic activity. It has a vasoconstrictor effect that reduces edema and congestion of the mucous membranes.
Topical nasal spray (2 times a day) or ophthalmic (3 - 4 times a day).
It is also used in facial cream to treat rosacea (Kuang 2018) and, mixed with local anesthetics, in dental anesthesia.
At the date of the last update, no published data was available in relation to breastfeeding.
The small dose and poor plasma absorption of most topical nasal, dermal, or ophthalmic preparations make it unlikely that a significant amount will pass into breast milk.
Measured plasma concentrations of oxymetazoline are low and its systemic effects are not clinically significant at the usual doses (Cartabuke 2019, Kuang 2018, Cacek 2017, Giannakopoulos 2012), so significant concentrations in milk are not to be expected.
Do not exceed the recommended dose and time to avoid undesirable side effects and the possible decrease in breast milk alluded to by some authors (Nice 2000), but not proven in practice.
Expert authors consider the use of this medication safe and probably compatible during breastfeeding (Hale 2019, Briggs 2017, Anderson 2000).
Ophthalmic administration is fully compatible with breastfeeding. Absorption can be minimized by pressing the tear duct (inner corner of the eye) with a finger for 1 minute.
Some authors consider oral and nasal decongestant drugs dispensable drugs, to be avoided in general, not only during lactation, since they expose patients to serious risks (cardiovascular, neurological and intestinal) to treat a benign disorder such as nasal obstruction, which usually progresses favorably within a few days without medication (Prescrire 2018).
A mother reported us irritability and insomnia for about 6 hours in her 7-month-old infant when she took oxymetazoline.